MapLight Therapeutics, Inc. (MPLT) Stock Statistics & Valuation Metrics

MapLight Therapeutics, Inc. has a market cap or net worth of $959.49M. The enterprise value is -$21.87M.

MapLight Therapeutics, Inc. has 42,436,325 shares outstanding. The number of shares has decreased by -2.65% in one year.

MapLight Therapeutics, Inc.’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -36.43%.

The current PE Ratio of MapLight Therapeutics, Inc. is ―. MapLight Therapeutics, Inc.’s PEG ratio is -0.05.

In the last 12 months, MapLight Therapeutics, Inc. had revenue of 0.00 and earned -161.15M in profits. Earnings per share was -3.66.

In the last 12 months, operating cash flow was -138.14M and capital expenditures -473.00K, giving a free cash flow of -138.61M billion.

MapLight Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

MapLight Therapeutics, Inc. upcoming earnings date is ―, ―.

MapLight Therapeutics, Inc. as a current ratio of 20.01, with Debt / Equity ratio of 1.27%

In the past 12 months, MapLight Therapeutics, Inc. has paid 0.00 in taxes.

MapLight Therapeutics, Inc. EV to EBITDA ratio is -4.35, with an EV/FCF ratio of -5.29.

MapLight Therapeutics, Inc. has $305.10M in cash and marketable securities with $5.80M in debt, giving a net cash position of $299.30M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for MapLight Therapeutics, Inc. is $36.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy